Medication info
Anarika Capsule 150 mg (Pregabalin)

Anarika Capsule 150 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›150mg / 1 capsule
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
A hard capsule with white at the top and white at the bottom containing a white powder that is white or light yellow.
Packaging
Domestic - 30 capsules/bottle, Export - 30 capsules/box [10 capsules/PTP*3], Export - 100 capsules/box [10 capsules/PTP*10]
Approval status
Active

MFDS item code 201109276 · Approved 2011.10.31 · Insurance code 654004040

Summary

Main use
Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys unchanged after passing through the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. * For females, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Method of administration / Initial dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age and adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia, adjunctive treatment of partial-onset seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunct therapy for patients with epilepsy experiencing partial seizures, with or without secondary generalized symptoms. Additionally, it is effective in alleviating pain in fibromyalgia patients. This medication is used to help improve symptoms related to various neurological disorders.

How to take

Adult dose

This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies were also conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted by the kidneys unchanged after passing through the systemic circulation. Since its clearance is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. * For females, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Method of administration / Initial dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: The supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Older adults (65 years of age or older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age and adolescent patients aged 12-17 years because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors; therefore, it is essential to inform healthcare professionals immediately if depressive symptoms or mood changes occur during treatment. Patients with allergies to any component of this medication should not take it. Patients with lactose intolerance should also avoid taking this medication. Diabetic patients may experience difficulty in blood sugar control due to weight gain, necessitating possible adjustments in antidiabetic medication doses. If symptoms of angioedema occur, stop taking the medication immediately and consult a healthcare professional. Elderly patients are at a higher risk of falling due to dizziness or drowsiness and should be cautious while using this medication. This medication may cause temporary blurred vision or changes in vision; if these symptoms occur, consult a healthcare professional. Abruptly discontinuing this medication may lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so it should be tapered off gradually in consultation with a healthcare professional. Patients with a history of substance abuse may have a higher risk of abusing this medication; caution is advised during use. Patients with impaired kidney function may require dose adjustments. Patients with severe heart disease should use this medication cautiously. Taking this medication with opioid analgesics increases the risk of central nervous system depression, so caution is warranted. Patients with respiratory or kidney conditions, as well as the elderly, may have a higher risk of severe respiratory depression and may require dose adjustments. In early pregnancy, there is a risk of fetal malformations; therefore, it is advisable not to take this medication during pregnancy, and fertile women should use effective contraceptive methods. This medication may pass into breast milk; therefore, consideration should be given to either stopping breastfeeding or discontinuing this medication. Dizziness or drowsiness may occur during driving or operating machinery, necessitating caution. Severe skin reactions may rarely occur; if skin abnormalities develop, stop taking the medication immediately and consult a healthcare professional. In the case of overdose, symptoms such as dizziness, confusion, depression, and seizures may occur, requiring immediate medical treatment. Store out of reach of children and avoid transferring to other containers.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial swelling
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 178 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like symptoms
  • restlessness
  • gloominess
  • suicidal thoughts
  • pain
  • seizures
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • restlessness
  • mood swings
  • emotional blunting
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination abnormality
  • balance disorder
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory loss
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • reflex impairment
  • motor disturbances
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing disorders
  • diplopia
  • vertigo
  • auditory hypersensitivity
  • first-degree heart block
  • tachycardia
  • bradycardia
  • certain types of arrhythmia
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramping
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • swelling
  • gait abnormalities
  • falls
  • feelings of intoxication
  • sensory anomalies
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • elevated blood glucose
  • reduced platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • facial paralysis
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best stored at room temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with white at the top and white at the bottom containing a white powder that is white or light yellow.

Package unit

Domestic - 30 capsules/bottle, Export - 30 capsules/box [10 capsules/PTP*3], Export - 100 capsules/box [10 capsules/PTP*10]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.